Advanced Pharmacotherapeutics
NURS 6521 WEEK 11 FINAL EXAM 2026/2027 WALDEN | 150
NGN-STYLE QUESTIONS AND EXPLAINED ANSWERS LATEST
VERSION
1. A patient with cirrhosis is prescribed a drug that is highly protein-
bound and undergoes extensive first-pass metabolism. Which
pharmacokinetic change should the nurse practitioner anticipate?
A. Increased renal clearance of the drug
B. Delayed onset of action due to slowed absorption
C. Decreased volume of distribution
D. Increased free drug fraction and higher risk of toxicity
ANSWER : D
Rationale: Hepatic disease lowers albumin synthesis, reducing protein
binding and increasing the free (active) fraction of highly bound drugs,
raising toxicity risk; first-pass metabolism is also impaired, further
increasing bioavailability.
2. Which patient is at greatest risk for altered drug clearance requiring
dose adjustment based on Cockcroft-Gault estimation?
A. An 82-year-old with a serum creatinine of 1.4 mg/dL and low muscle
mass
B. A 40-year-old with normal renal function and BMI of 22
C. A 30-year-old with a single normal creatinine value
D. A 25-year-old bodybuilder with a serum creatinine of 1.0 mg/dL
ANSWER : A
Rationale: Cockcroft-Gault relies on age, weight, and creatinine; elderly
patients with reduced muscle mass can have a 'normal-appearing'
creatinine despite significantly reduced GFR, masking true renal
impairment.
Page 1 of 51
, Advanced Pharmacotherapeutics
3. A drug has a narrow therapeutic index and is a CYP3A4 substrate.
The patient begins taking a strong CYP3A4 inhibitor. What is the
priority nursing action?
A. Increase the dose of the narrow therapeutic index drug
B. Monitor closely for signs of drug toxicity and consider dose reduction
C. No action needed since routes of elimination differ
D. Discontinue the CYP3A4 inhibitor without provider notification
ANSWER : B
Rationale: Strong CYP3A4 inhibition decreases metabolism of the substrate
drug, raising serum levels; with a narrow therapeutic index this
significantly increases toxicity risk and requires close monitoring or dose
adjustment.
4. Which statement best describes zero-order kinetics as seen with
phenytoin at higher doses?
A. Half-life remains constant regardless of dose
B. A constant percentage of drug is eliminated per unit time
C. A constant amount of drug is eliminated per unit time regardless of
concentration
D. Elimination rate increases proportionally with concentration
ANSWER : C
Rationale: In zero-order kinetics, elimination pathways become saturated so
a fixed amount (not percentage) of drug is cleared per unit time, causing
half-life to lengthen as dose increases.
5. A nurse practitioner is selecting a loading dose strategy for a drug
with a long half-life needed to achieve rapid therapeutic effect. What is
the rationale?
A. Loading doses reduce the total amount of drug needed overall
B. Loading doses decrease the volume of distribution
C. A loading dose achieves therapeutic plasma concentration faster than
waiting for steady state through maintenance dosing alone
D. Loading doses eliminate the need for maintenance dosing
ANSWER : C
Rationale: Steady state normally takes about 4-5 half-lives to reach; a
loading dose bypasses this delay by achieving therapeutic concentrations
immediately, which is important for drugs with long half-lives.
Page 2 of 51
, Advanced Pharmacotherapeutics
6. Which factor most directly affects the volume of distribution of a
lipophilic drug in an obese patient?
A. Increased fat mass decreases volume of distribution
B. Lipophilic drugs are unaffected by body composition
C. Obesity primarily affects renal clearance, not distribution
D. Increased fat mass provides an expanded reservoir, increasing volume
of distribution
ANSWER : D
Rationale: Lipophilic drugs partition into adipose tissue; in obesity, the
increased fat mass increases the apparent volume of distribution, which can
prolong the drug's half-life.
7. A patient taking warfarin is started on a medication that displaces
warfarin from plasma protein binding sites. What is the expected
clinical consequence?
A. Decreased anticoagulant effect requiring a dose increase
B. Transient increase in free warfarin activity and bleeding risk
C. Permanent increase in total warfarin plasma concentration
D. No clinically significant effect because warfarin is renally cleared
ANSWER : B
Rationale: Protein-binding displacement transiently raises the free, active
fraction of warfarin, increasing bleeding risk until redistribution and
compensatory clearance restore equilibrium.
8. Which pharmacodynamic concept explains why a patient develops
tolerance to opioid analgesia but not to opioid-induced constipation?
A. Tolerance develops uniformly across all opioid effects
B. Constipation is a pharmacokinetic, not pharmacodynamic, effect
C. All opioid effects share identical receptor mechanisms
D. Different receptor subtypes and pathways mediate analgesia versus GI
effects, each with distinct adaptive responses
ANSWER : D
Rationale: Tolerance develops variably depending on receptor subtype and
downstream signaling; mu-receptor mediated analgesia tolerance develops
faster than tolerance to GI motility effects.
Page 3 of 51
, Advanced Pharmacotherapeutics
9. A drug is administered intravenously and has a large volume of
distribution. What does this suggest about the drug's distribution
pattern?
A. The drug has a short elimination half-life
B. The drug remains primarily within the plasma
C. The drug distributes extensively into tissues rather than remaining in
the vascular compartment
D. The drug is poorly absorbed
ANSWER : C
Rationale: A large volume of distribution indicates the drug has left the
plasma and distributed into peripheral tissues, meaning plasma
concentration alone underestimates total drug in the body.
10. Which of the following best represents a Phase II hepatic metabolic
reaction?
A. Oxidation of a parent compound by CYP450 enzymes
B. Reduction of a ketone group
C. Hydrolysis of an ester bond by esterases
D. Glucuronidation of a drug metabolite to increase water solubility for
excretion
ANSWER : D
Rationale: Phase II reactions are conjugation reactions, such as
glucuronidation, sulfation, or acetylation, that increase water solubility to
facilitate renal or biliary excretion, typically following Phase I
oxidation/reduction/hydrolysis.
Cardiovascular Pharmacology
11. A patient newly started on lisinopril develops a persistent dry
cough. What is the underlying mechanism?
A. Histamine release causing airway inflammation
B. Direct bronchospasm from beta-2 receptor blockade
C. Accumulation of bradykinin due to ACE inhibition
D. Increased angiotensin II levels irritating the airway
ANSWER : C
Page 4 of 51
NURS 6521 WEEK 11 FINAL EXAM 2026/2027 WALDEN | 150
NGN-STYLE QUESTIONS AND EXPLAINED ANSWERS LATEST
VERSION
1. A patient with cirrhosis is prescribed a drug that is highly protein-
bound and undergoes extensive first-pass metabolism. Which
pharmacokinetic change should the nurse practitioner anticipate?
A. Increased renal clearance of the drug
B. Delayed onset of action due to slowed absorption
C. Decreased volume of distribution
D. Increased free drug fraction and higher risk of toxicity
ANSWER : D
Rationale: Hepatic disease lowers albumin synthesis, reducing protein
binding and increasing the free (active) fraction of highly bound drugs,
raising toxicity risk; first-pass metabolism is also impaired, further
increasing bioavailability.
2. Which patient is at greatest risk for altered drug clearance requiring
dose adjustment based on Cockcroft-Gault estimation?
A. An 82-year-old with a serum creatinine of 1.4 mg/dL and low muscle
mass
B. A 40-year-old with normal renal function and BMI of 22
C. A 30-year-old with a single normal creatinine value
D. A 25-year-old bodybuilder with a serum creatinine of 1.0 mg/dL
ANSWER : A
Rationale: Cockcroft-Gault relies on age, weight, and creatinine; elderly
patients with reduced muscle mass can have a 'normal-appearing'
creatinine despite significantly reduced GFR, masking true renal
impairment.
Page 1 of 51
, Advanced Pharmacotherapeutics
3. A drug has a narrow therapeutic index and is a CYP3A4 substrate.
The patient begins taking a strong CYP3A4 inhibitor. What is the
priority nursing action?
A. Increase the dose of the narrow therapeutic index drug
B. Monitor closely for signs of drug toxicity and consider dose reduction
C. No action needed since routes of elimination differ
D. Discontinue the CYP3A4 inhibitor without provider notification
ANSWER : B
Rationale: Strong CYP3A4 inhibition decreases metabolism of the substrate
drug, raising serum levels; with a narrow therapeutic index this
significantly increases toxicity risk and requires close monitoring or dose
adjustment.
4. Which statement best describes zero-order kinetics as seen with
phenytoin at higher doses?
A. Half-life remains constant regardless of dose
B. A constant percentage of drug is eliminated per unit time
C. A constant amount of drug is eliminated per unit time regardless of
concentration
D. Elimination rate increases proportionally with concentration
ANSWER : C
Rationale: In zero-order kinetics, elimination pathways become saturated so
a fixed amount (not percentage) of drug is cleared per unit time, causing
half-life to lengthen as dose increases.
5. A nurse practitioner is selecting a loading dose strategy for a drug
with a long half-life needed to achieve rapid therapeutic effect. What is
the rationale?
A. Loading doses reduce the total amount of drug needed overall
B. Loading doses decrease the volume of distribution
C. A loading dose achieves therapeutic plasma concentration faster than
waiting for steady state through maintenance dosing alone
D. Loading doses eliminate the need for maintenance dosing
ANSWER : C
Rationale: Steady state normally takes about 4-5 half-lives to reach; a
loading dose bypasses this delay by achieving therapeutic concentrations
immediately, which is important for drugs with long half-lives.
Page 2 of 51
, Advanced Pharmacotherapeutics
6. Which factor most directly affects the volume of distribution of a
lipophilic drug in an obese patient?
A. Increased fat mass decreases volume of distribution
B. Lipophilic drugs are unaffected by body composition
C. Obesity primarily affects renal clearance, not distribution
D. Increased fat mass provides an expanded reservoir, increasing volume
of distribution
ANSWER : D
Rationale: Lipophilic drugs partition into adipose tissue; in obesity, the
increased fat mass increases the apparent volume of distribution, which can
prolong the drug's half-life.
7. A patient taking warfarin is started on a medication that displaces
warfarin from plasma protein binding sites. What is the expected
clinical consequence?
A. Decreased anticoagulant effect requiring a dose increase
B. Transient increase in free warfarin activity and bleeding risk
C. Permanent increase in total warfarin plasma concentration
D. No clinically significant effect because warfarin is renally cleared
ANSWER : B
Rationale: Protein-binding displacement transiently raises the free, active
fraction of warfarin, increasing bleeding risk until redistribution and
compensatory clearance restore equilibrium.
8. Which pharmacodynamic concept explains why a patient develops
tolerance to opioid analgesia but not to opioid-induced constipation?
A. Tolerance develops uniformly across all opioid effects
B. Constipation is a pharmacokinetic, not pharmacodynamic, effect
C. All opioid effects share identical receptor mechanisms
D. Different receptor subtypes and pathways mediate analgesia versus GI
effects, each with distinct adaptive responses
ANSWER : D
Rationale: Tolerance develops variably depending on receptor subtype and
downstream signaling; mu-receptor mediated analgesia tolerance develops
faster than tolerance to GI motility effects.
Page 3 of 51
, Advanced Pharmacotherapeutics
9. A drug is administered intravenously and has a large volume of
distribution. What does this suggest about the drug's distribution
pattern?
A. The drug has a short elimination half-life
B. The drug remains primarily within the plasma
C. The drug distributes extensively into tissues rather than remaining in
the vascular compartment
D. The drug is poorly absorbed
ANSWER : C
Rationale: A large volume of distribution indicates the drug has left the
plasma and distributed into peripheral tissues, meaning plasma
concentration alone underestimates total drug in the body.
10. Which of the following best represents a Phase II hepatic metabolic
reaction?
A. Oxidation of a parent compound by CYP450 enzymes
B. Reduction of a ketone group
C. Hydrolysis of an ester bond by esterases
D. Glucuronidation of a drug metabolite to increase water solubility for
excretion
ANSWER : D
Rationale: Phase II reactions are conjugation reactions, such as
glucuronidation, sulfation, or acetylation, that increase water solubility to
facilitate renal or biliary excretion, typically following Phase I
oxidation/reduction/hydrolysis.
Cardiovascular Pharmacology
11. A patient newly started on lisinopril develops a persistent dry
cough. What is the underlying mechanism?
A. Histamine release causing airway inflammation
B. Direct bronchospasm from beta-2 receptor blockade
C. Accumulation of bradykinin due to ACE inhibition
D. Increased angiotensin II levels irritating the airway
ANSWER : C
Page 4 of 51
